Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained alive and 80% were disease free four years after treatment
Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years
Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence...
New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers
Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited
Patients with specific PPP2R1A mutations...
MD Anderson achieves sixth Magnet designation in recognition of nursing excellence
The American Nurses Credentialing Center (ANCC) Magnet Recognition Program is the highest honor of excellence in nursing
MD Anderson achieved...
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three subgroups with differential benefit from CD19 CAR T cell therapy
Study points to opportunities for alternative approaches to treat patients who do not benefit from CAR T cell therapies
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center...
MD Anderson and HealthEx announce collaboration to develop new platform to give patients direct control of data access
The University of Texas MD Anderson Cancer Center and HealthEx today announced a strategic collaboration aimed at developing tools for...
Mailed self-collection HPV tests boost cervical cancer screening rates
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S. populations...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes...
ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients...
ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs – encorafenib,...
Most Americans unaware of cancer risks associated with drinking alcohol
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40%...